Thanks for posting your free expert opinion on the PIII clinical trial, but we’ll leave the analyses & conclusions to the independent peer reviewers, the FDA, & the respected physicians who led the trial.
To clarify the mis- or disinformation, & for details about the DCVax®-L PIII clinical trial, the most comprehensive resource is the independent peer review that was published in JAMA Oncology.
☑️ There are multiple trials & trial designs relevant to NWBO that include either a DCVax product or Roswell’s aDC1 platform.
☑️ Beyond the PIII ECA, DCVax®-L is also being studied in a RCT setting with placebo group.
☑️ As a matter of record, OS was always one of the endpoints for the PIII, but OS replaced PFS as the primaryendpoint.